论文部分内容阅读
为了观察伊立替康联合顺铂治疗广泛期小细胞肺癌(SCLC)的近期疗效及毒副反应,对28例患者采用伊立替康联合顺铂治疗的方法。伊立替康60mg/m2,静脉滴入,d1、d8、d15;顺铂60mg/m2,静脉滴入,d1。28d为1个周期,2个周期后评价疗效。结果可评价疗效28例,其中CR6例(21.4%),PR12例(42.9%),NC4例(14.3%),PD6例(21.4%),总有效率为64.3%(18/28)。主要毒副反应为腹泻、骨髓抑制、恶心和呕吐。初步结果提示,伊立替康联合顺铂治疗SCLC有明显的疗效,毒副反应可以耐受,可以作为SCLC临床治疗的有效方案之一。
In order to observe the short-term curative effect and toxicity of irinotecan combined with cisplatin in the treatment of extensive stage small cell lung cancer (SCLC), 28 patients were treated with irinotecan combined with cisplatin. Irinotecan 60mg / m2, intravenous infusion, d1, d8, d15; cisplatin 60mg / m2, intravenous infusion, d1.28d for a period of 2 cycles after the evaluation of efficacy. Results The curative effect was evaluated in 28 cases. The total effective rate was 64.3% (18/28) in CR6 (21.4%), PR12 (42.9%), NC4 (14.3%) and PD6 (21.4%). The main side effects are diarrhea, myelosuppression, nausea and vomiting. The preliminary results suggest that irinotecan combined with cisplatin in the treatment of SCLC has obvious curative effect, toxicity can be tolerated and can be used as an effective solution for clinical treatment of SCLC.